Literature DB >> 21932176

Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism.

T Deutschbein1, M Broecker-Preuss, M F Hartmann, R Althoff, S A Wudy, K Mann, S Petersenn.   

Abstract

Urinary free cortisol (UFC) is used to assess disease activity in hypercortisolemic patients. However, reference ranges are often lacking, especially with respect to potential confounding variables. This study analyzed upper limits of normal (ULN, mean + 2 SD) for 2 newer immunoassays, using gas chromatography-mass spectrometry (GC-MS) as reference method. Each 10 healthy subjects were grouped by age (18-29; 30-49; ≥ 50 years), BMI (< 25; ≥ 25 kg/m2), and sex, resulting in a total of 120 controls (60 males; age: 39.3±1.3 years; BMI: 25.9±0.4 kg/m2). ULN were calculated for a radioimmunoassay (RIA, Immunotech) and an electrochemiluminescence immunoassay (ECLIA, Roche) and applied to 12 hypercortisolemic patients (4 males; age: 53.1±3.1 years; BMI: 29.1±1.8 kg/m2). To determine degradation, samples were stored at 4°C (without light) or 22°C (with and without light) for 0, 24, and 72 h. Cortisol concentrations were significantly correlated: r=0.88 for RIA vs. ECLIA, r=0.75 for RIA vs. GC-MS, and r=0.77 for ECLIA vs. GC-MS (always p<0.0001). For each procedure, multiple stepwise regression analysis identified sex as the only significant predictor, resulting in sex-dependent ULN (males vs. females): 294 vs. 208 nmol/24 h (RIA), and 379 vs. 277 nmol/24 h (ECLIA). These ULN classified samples from patients as hypercortisolemic in 100% (RIA) and 95% (ECLIA). Different storage conditions over 72 h did not alter UFC levels significantly. Results of the 3 procedures were well correlated, and the use of assay- and sex-specific ULN allowed excellent identification of hypercortisolic states. UFC is stable over 72 h irrespective of the storage conditions applied. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932176     DOI: 10.1055/s-0031-1286297

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome.

Authors:  Alessandro Prete; Rosa Maria Paragliola; Filomena Bottiglieri; Carlo Antonio Rota; Alfredo Pontecorvi; Roberto Salvatori; Salvatore Maria Corsello
Journal:  Endocrine       Date:  2016-07-09       Impact factor: 3.633

Review 2.  Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 3.  Adrenal insufficiency in pregnancy: challenging issues in diagnosis and management.

Authors:  Kevin C J Yuen; Lindsay E Chong; Christian A Koch
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

Review 4.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

5.  Dynamic Pituitary-Adrenal Interactions in the Critically Ill after Cardiac Surgery.

Authors:  Ben Gibbison; Daniel M Keenan; Ferdinand Roelfsema; Jon Evans; Kirsty Phillips; Chris A Rogers; Gianni D Angelini; Stafford L Lightman
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

Review 6.  Medical management of Cushing's disease: what is the future?

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 7.  Variability in laboratory parameters used for management of Cushing's syndrome.

Authors:  Francesca Pecori Giraldi; Alberto G Ambrogio
Journal:  Endocrine       Date:  2015-07-10       Impact factor: 3.633

Review 8.  Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?

Authors:  Gregori Casals; Felicia Alexandra Hanzu
Journal:  Ann Lab Med       Date:  2020-07       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.